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OBJECTIVEdTo examine whether circulating total and high–molecular weight (HMW) adi-
ponectin concentrations, measured before pregnancy, are associated with subsequent risk of
gestational diabetes mellitus (GDM).
RESEARCH DESIGN AND METHODSdThis was a nested case-control study among
women who participated in the Kaiser Permanente Northern California Multiphasic Health
Check-up exam (1984–1996) with a serum sample obtained and who had a subsequent preg-
nancy (1984–2009). Eligible womenwere free of recognized diabetes. Case subjects were the 256
women who developed GDM. Two control subjects were selected for each case and matched for
year of blood draw, age at exam, age at pregnancy, and number of intervening pregnancies.
RESULTSdCompared with the highest quartile of adiponectin, the risk of GDM increased
with decreasing quartile (odds ratio [OR] 1.5 [95% CI 0.7–2.9], 3.7 [1.9–7.2], and 5.2 [2.6–
10.1]; Ptrend,0.001) after adjustment for family history of diabetes, BMI, parity, race/ethnicity,
cigarette smoking, and glucose and insulin concentrations. Similar estimates were observed for
HMW (Ptrend,0.001). The combined effects of having total adiponectin levels below themedian
(,10.29 mg/mL) and being overweight or obese (BMI $25.0 kg/m2) were associated with a
sevenfold increased risk of GDM compared with normal-weight women with adiponectin levels
above the median (OR 6.7 [95% CI 3.6–12.5]).
CONCLUSIONSdPrepregnancy low adiponectin concentrations, a marker of decreased in-
sulin sensitivity and altered adipocyte endocrine function, is associated with reduced glucose
tolerance during pregnancy and may identify women at high risk for GDM to target for early
intervention.
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Gestational diabetes mellitus (GDM),deﬁned as glucose intolerancewith onset or ﬁrst diagnosis during
pregnancy, is a common complication
of pregnancy. Women with a history of
GDM have a sevenfold increased risk of
developing type 2 diabetes after delivery
(1), and the children of womenwith GDM
are more likely to be obese and develop
diabetes (2,3). The underlying etiology of
GDM appears to be similar to the physio-
logical abnormalities that characterize di-
abetes outside of pregnancy and is
thought to be due to an inability of the
pancreatic b-cells to compensate for the
increased insulin resistance induced by
pregnancy (4,5). The extent to which insu-
lin resistance or reduced insulin sensitivity
leading to GDM occurs even years before
pregnancy has not been determined in
population-based studies. There is increas-
ing interest in identifying prepregnancy
risk factors and biomarkers for GDM to in-
form future preconception prevention
strategies, given the proven success of spe-
ciﬁc prevention strategies for type 2 diabe-
tes in high-risk populations (6).
Adiponectin is an abundant adipocyte-
derived hormone demonstrated to have
actions consistent with protection against
insulin resistance, inﬂammation, and ath-
erosclerosis (7). Total adiponectin circu-
lates in the bloodstream as three discrete
complexes: a lower–molecular weight
trimer, a mid–molecular weight hexamer,
and a high–molecularweight (HMW) com-
plex (8). Some evidence suggests that
HMW adiponectin is the isoform that me-
diates the insulin-sensitizing and antia-
therogenic effects (9,10). Prospective
studies examining adiponectin and inci-
dent type 2 diabetes reported that lower
circulating total adiponectin concentra-
tions were associated with a higher risk of
type 2 diabetes in a dose-response relation-
ship (11). Both total adiponectin (12) and
HMW adiponectin (13) are known to de-
crease signiﬁcantly in normal pregnan-
cies in response to decreased insulin
sensitivity; therefore, it is important to
determine whether prepregnancy levels
of adiponectin are related to subsequent
risk of GDM in order to clarify the tem-
poral sequence of the association. The
aim of this study is to examine the asso-
ciation between prepregnancy total and
HMW adiponectin concentrations and
the risk of developing GDM and to deter-
mine whether these associations are inde-
pendent of known metabolic risk factors
for GDM.
RESEARCH DESIGN AND
METHODSdThe setting was Kaiser
Permanente Northern California (KPNC),
an integrated health care delivery system
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that providesmedical care for approximately
one-third of the underlying population
in the San Francisco Bay area. KPNC
subscribers are representative of the
region (14).
The source population consisted of
women KPNCmembers who completed a
voluntary Multiphasic Health Checkup
(MHC) at the Kaiser Permanente Oakland
Medical Center between 1984 and 1995.
KPNC members at this facility were in-
vited to complete a comprehensive health
check-up upon enrollment. The MHC
consisted of a clinic visit for the comple-
tion of questionnaires and clinical mea-
surements, including blood pressure,
weight, and serum glucose and choles-
terol (measured in serum obtained from a
random blood draw). An extra serum
sample was collected and stored at
2408C for future use. The goal of the
MHC was to provide health maintenance
through early diagnosis (15). BMI was
calculated as weight in kilograms divided
by the square of height in meters; height
was measured using a stadiometer and
weight using a balance beam scale. Infor-
mation on age, sex, race/ethnicity, educa-
tion level, cigarette smoking, family
history of diabetes, medical history, alco-
hol consumption, coffee consumption,
and use of medications and hours since
last food ingestion was collected using
self-administered questionnaires (15). Se-
rum glucose was measured on serum ob-
tained from a random blood draw using
the hexokinase method, and total choles-
terol was assessed using a Kodak Ektachem
Chemistry analyzer by the regional labora-
tory of KPNC at the time of theMHC exam.
This laboratory participates in the College
of American Pathologists’ accreditation and
monitoring program.
Among women 15–45 years of age
who participated in the MHC from 1985
to 1996 (n = 27,743 with clinical and
questionnaire data, as well as an extra
serum sample), we identiﬁed 4,098
women who subsequently delivered an
infant by 2010 by searching the KPNC
hospitalization database and the Preg-
nancy Glucose Tolerance and GDM Reg-
istry (16), an active surveillance registry
that annually identiﬁes all pregnancies
resulting in a live birth or stillbirth among
KPNC members. Women with recog-
nized pregravid diabetes (17) are ex-
cluded from the GDM Registry. It also
captures the results of all screening and
diagnostic tests for GDM from KPNC’s
electronic laboratory database (data avail-
able since 1994).
Table 1dCharacteristics of case and control subjects
GDM case
subjects
Control
subjects P
N 256 497
Age at MHC exam (years) 28.2 6 5.5 28.4 6 5.2 0.78a
Age at delivery (years) 35.4 6 5.1 35.1 6 4.9 0.43b
,30 39 (15.2) 80 (16.1)
30–34 73 (28.5) 145 (29.2)
35–39 102 (39.8) 183 (36.8)
$40 42 (16.4) 89 (17.9)
Time between exam and delivery (years) 7.1 6 4.4 6.7 6 4.4 0.21a
Education (years) 0.24b
#12 74 (28.9) 119 (23.9)
13–15 85 (33.2) 157 (31.6)
$16 92 (35.9) 214 (43.1)
Unknown 5 (2.0) 7 (1.4)
Race/ethnicity ,0.001b
Non-Hispanic white 50 (19.5) 186 (37.4)
African American 91 (35.5) 184 (37.0)
Asian/Paciﬁc Islander 80 (31.3) 84 (16.9)
Hispanic 35 (13.7) 43 (8.7)
Parity ,0.001b
0 142 (55.5) 278 (55.9)
1 47 (18.4) 106 (21.3)
$2 44 (17.2) 70 (14.1)
Unknown 23 (9.0) 43 (8.7)
Gestational age at birth (weeks) 0.01b
$37 218 (84.8) 460 (90.7)
,37 39 (15.2) 39 (7.7)
Large-for-gestational age at birthc ,0.01b
No 198 (81.1) 427 (89.5)
Yes 46 (18.9) 50 (10.5)
Alcohol ,0.001b
None 74 (28.9) 81 (16.3)
Occasional or more drinks/day 149 (58.2) 346 (69.6)
Unknown 33 (12.9) 70 (14.1)
Smoking 0.40b
Never 150 (58.6) 277 (55.7)
Former 37 (14.5) 92 (18.5)
Current 38 (14.8) 61 (12.3)
Unknown 31 (12.1) 67 (13.5)
Hypertension status at index pregnancy ,0.001b
No hypertension 138 (53.9) 326 (65.5)
Preexisting hypertensiond 28 (10.9) 18 (3.6)
Gestational hypertension 33 (12.9) 68 (13.7)
Preeclampsia 42 (16.4) 37 (7.4)
Family history of diabetes ,0.001b
Yes 151 (59.0) 192 (38.6)
BMI (kg/m2) 26.0 6 6.5 23.7 6 4.6 ,0.001b
Weight change from MHC to
pregnancy (kg)
8.9 6 9.9 4.4 6 8.2 ,0.001a
Rate of gestational weight gain (kg/week)e 0.3 6 0.2 0.4 6 0.2 ,0.05b
Serum glucose (mg/dL) 89.6 6 13.5 83.6 6 8.3 ,0.001a
Serum cholesterol (mg/dL) 182.9 6 33.2 176 6 32.6 ,0.01a
Systolic blood pressure (mmHg) 115.6 6 14.7 113.3 6 13.4 ,0.05a
Diastolic blood pressure (mmHg) 69.9 6 10.4 68.3 6 9.0 ,0.05a
White blood cell count (1,000 cells/mm3) 6.9 6 1.9 6.5 6 1.9 ,0.01a
HMW adiponectin (mg/mL) 2.8 6 1.5 4.0 6 2.0 ,0.001f
Continued on p. 3932
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Study design
This is a nested case-control study
within a cohort of 4,098 women who
took part in an MHC exam, had an extra
tube of serum stored for future use, and
had a subsequent pregnancydon aver-
age, 6 years after the MHC exam. All co-
hort members who went on to develop
GDM were included as case subjects;
two control subjects were selected for
each case from among women not meet-
ing the GDM case deﬁnition.
GDM case deﬁnition
We identiﬁed 267 women with GDM
according to the KPNC electronic data-
bases: case subjects had either 1) glucose
values obtained during a standard 100-g,
3-h oral glucose tolerance test that met the
American College of Obstetricians and
Gynecologists plasma glucose thresholds
for GDM (18) in the laboratory database
(n = 228) or 2) a hospital discharge diag-
nosis of GDM in the electronic hospital
discharge database for pregnancies occur-
ring before the electronic laboratory data
were available (prior to 1994; n = 39).
Standardized medical chart review was
conducted by trained abstractors to con-
ﬁrm that these 267 women had a 100-g,
3-h oral glucose tolerance test meeting the
American College of Obstetricians and
Gynecologists criteria (18) for GDM
(plasma glucose thresholds: fasting 5.3
mmol [95 mg/dL], 1 h 10.0 mmol/L
[180 mg/dL], 2 h 8.6 mmol/L [155 mg/dL],
and 3 h 7.8 mmol/L [140 mg/dL]). Case
subjects were excluded if at the time of
the MHC exam they had a random glu-
cose .200 mg/dL (n = 6), no indication
of GDM during the index pregnancy (n =
4) or impaired glucose tolerance with in-
sufﬁcient follow-up testing (n = 1),
leaving a total of 256 conﬁrmed cases of
GDM.
Control selection and matching
criteria
From among those women without an
indication of GDM, control subjects were
randomly selected; two control subjects
were individuallymatched to each case on
year of MHC serum collection date (63
months), age atMHC serum collection (62
years), number of intervening pregnancies
(0, 1,$2), and age at delivery of the index
pregnancy (62 years). We matched
for the year of serum collection to account
for any potential degradation in the qual-
ity of the serum over time, thereby as-
suring the sample storage time was
approximately the same for case and con-
trol subjects. Since GDM is more common
in older women, we matched on age at
serum collection and age at delivery. We
matched on number of pregnancies to ac-
count for any differences in pregnancies
between the initial exam and the index
pregnancy. Control subjects were ex-
cluded from the analysis if they had glu-
cose values diagnostic of GDM found
during medical chart abstraction (n = 5),
had an abnormal screening glucose but
no follow-up diagnostic glucose test
(n = 5), or had one abnormal glucose
value on the diagnostic glucose test (n =
5), suggestive of “mild” GDM. Of the 512
matched control subjects identiﬁed, 497
were eligible.
Exposure variables
Serum biomarker assays. Serum sam-
ples were thawed, aliquoted, and transported
in batches on dry ice to the laboratory of
P.J.H. at the University of California, Davis,
for analysis. Serum adiponectin was mea-
sured with a commercially available radio-
immunoassay (Millipore [formerly Linco
Research]) using 125I-labeledmurine adipo-
nectin and a multispecies anti-adiponectin
antibody. The assay has a sensitivity of
1 ng/mL and a linearity of 200 ng/mL.
The intra- and interassay coefﬁcients of
variation are ,6.0% and ,9.0%, respec-
tively. HMW adiponectin was measured
with a commercially available ELISA kit
(cat. no. EZHMWA-64 K; Millipore), a
method that has recently been validated
against Western blot analysis (19). Insulin
was measured with a radioimmunassay
(Millipore); the intra-assay and interassay
coefﬁcients of variation are ,4.0% and
,10%, respectively.
Statistical analysis
Conditional logistic regression was used
to obtain odds ratios (ORs) to estimate the
relative risk of GDM in relation to pre-
pregnancy adiponectin levels. Associa-
tions of prepregnancy adiponectin levels
with prepregnancy BMI, age, and glucose,
insulin, and cholesterol levels were esti-
mated with Spearman correlation coefﬁ-
cients. Women were categorized by
quartile of adiponectin levels as deﬁned
among control subjects. Variables evalu-
ated for confounding included race/
ethnicity, pregravid BMI, parity, cigarette
smoking, and family history of diabetesd
all assessed at the time of adiponectin
measurement. To assess confounding,
we entered covariates into a logistic re-
gression model, one at a time, and com-
pared the adjusted and unadjusted
estimates. We ﬁrst included covariates
that altered unadjusted estimates by
$10%.We then added potential interme-
diary variables of the effects of adiponec-
tin on GDM: prepregnancy glucose and
insulin levels (and further adjusted for
hours since last food intake) for these
models.
To assess the potential modifying
effects of prepregnancy BMI (overweight
or obese$25 kg/m2 vs. not overweight or
obese ,25 kg/m2), race/ethnicity (white,
Asian, Hispanic, and African American),
and median time since MHC exam ($6.2
years vs.,6.2 years), we included appro-
priate cross-product (interaction) terms
in regression models. To examine the ef-
fects of weight gain after the MHC exam,
we added weight gain to the fully adjusted
conditional logistic regression model
(20). This study was approved by the hu-
man subjects committee of the Kaiser
Foundation Research Institute.
RESULTSdTable 1 summarizes the de-
mographic, anthropometric, reproduc-
tive, and metabolic characteristics of the
study participants by case-control status.
Table 1dContinued
GDM case
subjects
Control
subjects P
Total adiponectin (mg/mL) 7.7 6 3.5 10.6 6 4.4 ,0.001f
Insulin (mU/mL) 25.8 6 28.6 17.5 6 16.7 ,0.001f
HOMA-IR indexg 4.1 6 3.5 2.9 6 2.9 ,0.001f
Data are N (%) or means 6 SD unless otherwise indicated. at test to compare differences in mean values of
continuous variables except as noted below for Wilcoxon test. bx2 test for categorical variables. cSubset of
women with singleton births; large-for-gestational age .90th percentile based on race and gestational age–
speciﬁc quantiles. dIncludes women who experienced preeclampsia superimposed on preexisting hyper-
tension. eWeight change in kilograms per week from beginning of index pregnancy until screening glucose
(measurement obtained 1 h after the 50-g oral challenge). Data were available for 226 case and 407 control
subjects. fWilcoxon test for differences in median values. gSubset of women fasting for .6 h at the time of
MHC exam (case subjects, n = 149; control subjects, n = 269).
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Prepregnancy adiponectin and GDM
Women who developed GDM were more
likely to have ,12 years of education, to
be Asian or Hispanic, to be nulliparous at
the time of the exam, to abstain from al-
cohol, and to have a family history of type
2 diabetes compared with women who
did not develop GDM. Women who de-
veloped GDM also had higher levels of
several cardiometabolic risk factors in-
cluding BMI at the MHC exam, serum
glucose, total cholesterol, systolic and di-
astolic blood pressure, serum insulin con-
centrations, and weight gain from the
MHC exam to the index pregnancy.
Mean prepregnancy HMW and total adi-
ponectin concentrations were both signif-
icantly lower in women who developed
GDM compared with those who did not
develop GDM (2.8 vs. 4.0 and 7.7 vs.
10.6, respectively; P value,0.001). Table
2 shows the correlation of serum total and
HMW adiponectin levels with several
metabolic covariates separately for case
and control subjects (Table 2).
As presented in Table 3, women in the
lowest quartile of total adiponectin distri-
bution (1.2–7.2 mg/mL) prior to preg-
nancy experienced a ﬁvefold increased
risk of GDM compared with women
whose values fell within the highest quar-
tile (13.1–25.2 mg/mL, OR 5.18 [95% CI
2.65–10.11]) after adjustment for race/
ethnicity, BMI, parity, family history of
diabetes, smoking status at time of MHC
exam, insulin, glucose, and fasting status.
Since gaining $5.0 kg from the time of
MHC exam to pregnancy was associated
with a 3.6-fold increased risk of GDM
compared with women who maintained
or lost weight (#0.5 kg) (OR 3.6 [95% CI
2.15–6.03]), weight gainwas added to the
model and similar results were obtained
(results not shown).
When the combined effects of adipo-
nectin levels and maternal BMI were
examined, among normal-weight women
(BMI ,25.0 kg/m2), having low concen-
trations of total adiponectin (deﬁned as
,10.29 mg/mL) was associated with a
3.5-fold increased risk of GDM compared
with high total adiponectin levels (de-
ﬁned as $10.29 mg/mL). Women who
were overweight or obese (BMI $25.0
kg/m2) and had high adiponectin concen-
trations had a twofold increased risk of
GDM compared with normal-weight
women with the same adiponectin con-
centrations. Women who both were over-
weight and had low total adiponectin had
6.8-fold increased risk of GDM. Similar
results were observed with HMW adipo-
nectin (Fig. 1).
The association remained also when
women were stratiﬁed by median time
since MHC exam. In a stratiﬁed analysis
examining quartiles of total adiponectin
and GDM risk, the ORs for the lowest
compared with highest quartile of adipo-
nectin were similar when the time since
initial examwas years.6.2 years (theme-
dian time since exam), 5.0 (95% CI 2.0–
12.0), compared with when it had been
,6.2 years since the exam, 4.2 (2.0–9.1);
there was no signiﬁcant interaction by
time since exam (P = 0.66). There was
also no signiﬁcant interaction by pregravid
BMI or race/ethnicity.While the interaction
with race was not statistically signiﬁcant,
we found some suggestion that the associ-
ation between adiponectin and GDM risk
may be stronger for Asians and Hispanics
for continuous adiponectin: white OR 0.86
(95% CI 0.77–0.96), black 0.89 (0.82–
0.98), Asian/Paciﬁc Islander 0.77 (0.67–
0.88), and Hispanic 0.62 (0.42–0.91).
A sensitivity analysis restricted to the
149 case and 269 control subjects who
had fasted for .6 h found similar ad-
justed ORs associated with being in the
lower two quartiles of adiponectin and
GDM risk (quartile 2, 3.4 [95% CI 1.6–
7.1], and quartile 1, 4.3 [95% CI 2.0–
9.4]), compared with quartile 4. Among
this subset, we further adjusted for ho-
meostasis model assessment of insulin re-
sistance (HOMA-IR) and found that the
ORs associated with being in the lower
two quartiles of adiponectin were slightly
attenuated but remained signiﬁcant
(quartile 2, 3.2 [95% CI 1.5–6.9], and
quartile 1, 3.7 [95% CI 1.7–8.1] com-
pared with quartile 4).
Finally, we examined the association
between adiponectin and GDM among a
subset of women without the strongest
risk factors for GDM: women who were
normal weight (BMI ,25.0 kg/m2) and
had no family history of GDM (n = 55
case and n = 224 control subjects).
Among this subset of low-risk women,
the OR associated with continuous adi-
ponectin was 0.70 (95% CI 0.56–0.88)
for HMW and 0.84 (95% CI 0.76–0.92)
for total adiponectin after adjustment for
matching variables, BMI (continuous),
parity, and race.
CONCLUSIONSdIn this nested case-
control study, we found that lower adi-
ponectin concentrations measured, on
average, 6 years before pregnancy were
associated with a 5.0-fold increased risk
of developing GDM. We found similar
associations between total and HMW
adiponectin and GDM even when the
measurement occurred $6 years before
pregnancy, conﬁrming the robustness of
the association. Of note, these relationships
were independent of known risk factors
for GDM, including BMI, age, and race/
ethnicity, as well as markers of insulin re-
sistance (speciﬁcally, glucose and insulin)
that have been associated with adiponectin
(7) concentrations and the development
Table 2dPearson correlation coefﬁcients of pregravid maternal plasma total and HMW adiponectin with selected (pregravid) maternal
characteristics
Total adiponectin HMW adiponectin
GDM case subjects Control subjects GDM case subjects Control subjects
n 256 497 256 497
Maternal age at exam (years) 20.17 (,0.01) 0.06 (0.16) 20.16 (0.01) 0.09 (0.05)
BMI (kg/m2) 20.20 (,0.01) 20.04 (0.41) 20.19 (,0.01) 20.01 (0.80)
Serum glucose (mg/dL) 20.20 (,0.01) 20.23 (,0.0001) 20.23 (,0.001) 20.23 (,0.0001)
Serum insulin (mU/mL) 20.12 (,0.05) 20.03 (0.45) 20.12 (0.05) 20.07 (0.12)
Serum cholesterol (mg/dL) 20.25 (,0.0001) 20.14 (,0.01) 20.26 (,0.0001) 20.16 (,0.001)
HOMA-IR index* 20.36 (,0.0001) 20.08 (0.17) 20.37 (,0.0001) 20.11 (0.07)
Data are r (P) unless otherwise indicated. *Subset of women fasting for .6 h at the time of MHC exam (case subjects, n = 149; control subjects, n = 269).
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of reduced glucose tolerance in both
pregnant and nonpregnant populations
(21,22). These associations were not me-
diated by subsequent weight gain. Our
ﬁndings are among the ﬁrst to suggest
that low circulating adiponectin concen-
trations may predict GDM years prior to
pregnancy and extend existing knowl-
edge pertaining to pregravid risk factors
for GDM. We found that the association
between prepregnancy adiponectin and
GDM risk remained a signiﬁcant risk fac-
tor for GDM among the subset of women
whowere normal weight and had no fam-
ily history of GDM: two strong risk fac-
tors for GDM. This ﬁnding is of clinical
relevance because it suggests that adipo-
nectin may help identify a group of high-
risk women who may otherwise not be
identiﬁed as being at high risk of devel-
oping GDM.
Our ﬁndings are consistent with pre-
vious studies of adiponectin and type 2
diabetes. A systematic review and meta-
analysis of prospective studies examining
adiponectin and incident type 2 diabetes
found that higher adiponectin levels were
associated with a 30% lower risk of type 2
diabetes (relative risk [RR] 0.72 [95% CI
0.67–0.78]) per 1 logmg/mL increment in
adiponectin levels, consistent with a
dose-response relationship (11). Less is
known about the role of adiponectin in
GDM risk. A couple of studies assessing
the prospective association between adi-
ponectin levels in the ﬁrst trimester of
pregnancy and the risk of GDM found
that women with GDM had lower levels
of adiponectin compared with women
who did not develop GDM (23–25),
which is consistent with the current
study. Other previous studies (26)
with a small sample size examined adipo-
nectin levels during the third trimester
and GDM (24,27). However, since both
total adiponectin (12) and HMW adipo-
nectin (13) have been shown to decrease
signiﬁcantly in normal pregnancies, the
previous studies were not able to assess
whether the association between adipo-
nectin and increased risk of GDM was re-
lated only to the physiologic changes that
accompany normal pregnancy. Pregnancy-
induced changes such as rapid increases
in body weight and fat, insulin resistance,
inﬂammation, and lipids are related
to both lower adiponectin and reduced
glucose tolerance (7). The ﬁndings of
our prospective study suggest that al-
tered adiponectin levels in women with
normal glucose metabolism years before
pregnancy may lead to decreased glucose
tolerance during pregnancy, such as
GDM.
There is biologic plausibility for an
important role of adiponectin in GDM
risk. The underlying etiology of GDM is
believed to be diminished insulin secretion
prepregnancy coupled with pregnancy-
induced insulin resistance (5). These re-
sults add more evidence to support this
possible mechanism. Adiponectin has
been shown to promote b-cell function
and survival and decrease hepatic
glucose output (thereby lowering systemic
glucose levels) (28). Therefore, low
adiponectin levels may lead to both re-
duced insulin secretion and increased in-
sulin resistance. In human studies,
adiponectin has been shown to be in-
versely related to visceral adiposity (29)
and liver fat accumulation (30) and posi-
tively correlated with truncal fat, all of
which have been shown to be associated
with insulin resistance and diabetes risk
independent of BMI (28).
We found no evidence that weight
gain either before pregnancy affected the
association between adiponectin and
GDM regardless of baseline BMI. How-
ever, adiponectin levels have been shown
to increase after signiﬁcant weight loss
either by caloric restriction or from
weight loss surgery (gastric bypass) (28),
and medications that increase the num-
ber of small adipocytes, such as thia-
zolidinediones, also increase adiponectin
production (31). While this suggests that
adiponectin can be modiﬁed, more infor-
mation is needed to determine strategies for
increasing circulating adiponectin concen-
trations to better inform possible preven-
tion strategies for both GDM and type 2
diabetes.
Strengths of this study include our
ability to exclude women with glucose
values indicative of recognized, pregesta-
tional diabetes. We had the unique ability
to look at adiponectin levels measured
several years before pregnancy on a large
number of GDM case and matched con-
trol subjects. We were able to control for
markers of insulin resistance (HOMA-IR)
among a subset, and our ﬁndings re-
mained when adjusted for potential me-
diators. The study was limited by the lack
of data on more informative measures of
adiposity in addition to BMI, such as waist
circumference or percent body fat, andwe
therefore were not able to assess whether
the association between adiponectin and
GDMwas possibly mediated by increased
visceral fat. We also lacked information
on diet and physical activity changes that
may have occurred from the baseline
exam to the subsequent pregnancy;
therefore, we were unable to assess the
impact of lifestyle changes on GDM
risk in this study. We only had a single
measurement of adiponectin, which may
be subject to variation; such misclassiﬁ-
cation would be nondifferential and bias
our results toward the null hypothesis.
Finally, our samples were nonfasting;
however, the majority of studies have
found either no or only a minor effect of
Table 3dORs (95% CI) for GDM associated with prepregnancy circulating adiponectin
concentrations from conditional logistic regression models
Prepregnancy risk factor
Conditional logistic regression models
Crude
Multivariable
adjusteda
Multivariable
adjustedb
Total adiponectin (mg/mL)
Continuous 0.82 (0.78–0.86) 0.83 (0.78–0.88) 0.83 (0.78–0.88)
Quartile 1 (1.18–7.19) 5.61 (3.31–9.50) 4.69 (2.56–8.57) 5.18 (2.65–10.11)
Quartile 2 (7.20–10.28) 3.22 (1.89–5.50) 3.34 (1.82–6.13) 3.71 (1.90–7.24)
Quartile 3 (10.29–13.12) 1.18 (0.65–2.14) 1.16 (0.60–2.22) 1.45 (0.73–2.88)
Quartile 4 (13.13–25.22) 1.00 1.00 1.00
HMW adiponectin (mg/mL)
Continuous 0.65 (0.58–0.73) 0.68 (0.60–0.78) 0.67 (0.58–0.78)
Quartile 1 (0.45–2.48) 5.88 (3.44–10.08) 4.74 (2.54–8.84) 5.25 (2.63–10.48)
Quartile 2 (2.49–3.70) 3.14 (1.83–5.40) 2.93 (1.60–5.38) 3.39 (1.73–6.63)
Quartile 3 (3.71–4.96) 1.37 (0.76–2.48) 1.20 (0.63–2.29) 1.46 (0.74–2.88)
Quartile 4 (4.97–11.31) 1.00 1.00 1.00
aAdjusted for race/ethnicity, BMI, parity, family history of diabetes, and smoking status at time of MHC exam.
bFurther adjusted for insulin, glucose (as tertiles), and fasting status (deﬁned as$6 h since last food at time of
MHC exam).
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Figure 1dORs for association between joint effects of pregravid adiponectin and BMI and risk of GDM. A: Total adiponectin. B: HMW adiponectin.
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feeding/fasting on circulating adiponec-
tin concentrations (7), and our ﬁndings
were similar in the subanalysis restricted
to women who fasted for $6 h.
In summary, after adjusting for po-
tential confounding factors and clinical
factors known to be related to insulin
resistance, we found that low adiponectin
concentrations, measured on average 6
years prior to pregnancy, were associ-
ated with a ﬁvefold increased risk of
GDM. Circulating concentrations of to-
tal and HMW adiponectin represent
potentially useful new biomarkers re-
garding who is at risk for GDM beyond
the currently established clinical and
demographic risk factors. Future studies
designed to be able to assess the sensi-
tivity and speciﬁcity of adiponectin in
predicting GDM will be valuable to help
further clarify the clinical utility of these
biomarkers.
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